Share Twitter LinkedIn Facebook Email Douglas G. McNeel, MD of @UWCarbone discusses the phase II trial of a DNA vaccine encoding in patients with nonmetastatic, castration-sensitive prostate cancer. ______ Read here:Â https://ascopubs.org/doi/abs/10.1200/JCO.19.01701?journalCode=jco&
MOASC Awards $25,000 Research Grant from AVEO Oncology to Dr. Peter Zang, MD of City of Hope 2025 Cary Presant, MD Investigator Award Prostate 4 Mins Read
Overview of SYNC-T Technology from Syncromune in Prostate Cancer Treatment – Charles Link, MD Prostate 2 Mins Read